3
Announcements
Trials
Browse
Landscape
Phase
Phase 2
3
Phase 1
1
Status
Unknown
1
Sponsor Class
OTHER
1
Study Type
Interventional
1
Sponsor
Cancer Type
Thoracic
1
Genitourinary
1
Gastrointestinal
1
Breast
1
Conditions
Breast Neoplasms
36
Neoplasms
9
Precursor Cell Lymphoblastic Leukemia-Lymphoma
5
Neoplasm Metastasis
5
Pancreatic Neoplasms
4
Ovarian Neoplasms
3
Lymphoma, Mantle-Cell
3
Lung Neoplasms
3
Leukemia, Myeloid, Acute
3
Advanced Breast Cancer
3
Sarcoma
2
Recurrence
2
Prostatic Neoplasms
2
Multiple Myeloma
2
Melanoma
2
Lymphoma, Non-Hodgkin
2
Inflammation
2
Hereditary Sensory and Autonomic Neuropathies
2
Head and Neck Neoplasms
2
Colorectal Neoplasms
2
Urinary Bladder Neoplasms
1
Triple Negative Breast Neoplasms
1
Thrombosis
1
Thromboembolism
1
Thrombocytosis
1
Squamous Cell Carcinoma of Head and Neck
1
Primary Myelofibrosis
1
Oligodendroglioma
1
Neoplasms, Neuroepithelial
1
Myeloproliferative Disorders
1
Interventions
Oxaliplatin
31
Fluorouracil
31
Leucovorin
29
Irinotecan
23
Cetuximab
20
Bevacizumab
16
Capecitabine
13
Gemcitabine
11
pembrolizumab
8
Folfox protocol
7
Cisplatin
7
Carboplatin
7
Paclitaxel
6
Nivolumab
6
Cyclophosphamide
6
trifluridine tipiracil drug combination
5
cediranib
5
Erlotinib Hydrochloride
5
adagrasib
4
Ipilimumab
4
IFL protocol
4
Floxuridine
4
Bortezomib
4
veliparib
3
trametinib
3
sargramostim
3
poly ICLC
3
binimetinib
3
Trifluridine
3
Sorafenib
3
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
Phase 1
×
Colonic Neoplasms
×
palbociclib
×
Clear all
NCT06065592
2023-10-06
CAT_PB
Lebanese University
Phase 1
Unknown
500 enrolled